Adaptive Biotechnologies Corporation
ADPTNASDAQHealthcare● Active
$16.92
+$0.02(+0.13%)
Market Cap$2.7B
P/E Ratio—
52W High$20.76
52W Low$9.78
Adaptive Biotechnologies Corporation (ADPT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ADPT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.28B | $0.18B | $0.17B | $0.19B | $0.15B |
| Cost of Revenue | $0.07B | $0.07B | $0.08B | $0.06B | $0.05B |
| Gross Profit | $0.21B | $0.11B | $0.09B | $0.13B | $0.11B |
| Gross Margin %(computed) | 74.24% | 59.72% | 55.63% | 68.75% | 68.06% |
| Operating Expenses | |||||
| R&D Expenses | $0.09B | $0.10B | $0.12B | $0.14B | $0.14B |
| G&A Expenses | $0.07B | $0.07B | $0.08B | $0.09B | $0.07B |
| Total Operating Expenses | $0.26B | $0.27B | $0.32B | $0.33B | $0.31B |
| Operating Income | ($0.06B) | ($0.16B) | ($0.23B) | ($0.20B) | ($0.21B) |
| Operating Margin %(computed) | -20.62% | -90.83% | -133.33% | -108.03% | -135.39% |
| Interest Income | $0.01B | $0.01B | $0.02B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Income Before Tax | ($0.06B) | ($0.16B) | ($0.23B) | ($0.20B) | ($0.21B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.06B) | ($0.16B) | ($0.23B) | ($0.20B) | ($0.21B) |
| Net Margin %(computed) | -21.48% | -89.12% | -132.29% | -108.03% | -134.30% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.39 | $-1.08 | $-1.56 | $-1.00 | $-1.46 |
| Wtd Avg Shares | 0.15B | 0.15B | 0.14B | 0.14B | 0.14B |
| EBITDA | ($0.03B) | ($0.13B) | ($0.19B) | ($0.18B) | ($0.19B) |
| EBITDA Margin %(computed) | -10.78% | -71.95% | -111.16% | -94.55% | -125.27% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Adaptive Biotechnologies Corporation data
About Adaptive Biotechnologies Corporation (ADPT) Income Statement
Adaptive Biotechnologies Corporation (ADPT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ADPT reported revenue of $0.28B, gross profit of $0.21B (gross margin 74.24%), and net income of ($0.06B) — a net profit margin of -21.48%.
Frequently asked questions
ADPT · 4 questionsAdaptive Biotechnologies Corporation (ADPT) reported revenue of $0.28B for 2025, up 54.8% year-over-year.
ADPT revenueADPT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08